I can see both perspectives. Gilead already and currently owns the HIV market and their struggles were growth (due to Hep C cure / revenues falling off drastically). Why look for growth in the market you already dominate?....Let’s buy CAR-T and get into the new hot thing in cancer. It may work out in the long term, but I think CYDY will work out much better. I held my GILD shares for awhile thinking they would buyout CYDY or license leronlimab and I wanted the upside in this paradigm shift. I have since sold all GILD and put those funds into CYDY. Our chances of 10x+ with CYDY are much better than 2x GILD IMO (even if they end up licensing HIV).